|Other names||4-Chlordehydromethyltestosterone; Dehydrochloromethyltestosterone; 4-Chloromethandienone|
|Drug class||Androgen; anabolic steroid|
|Elimination half-life||16 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||334.88 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Chlorodehydromethyltestosterone (CDMT; brand name Oral Turinabol), also known as 4-chloro-17β-hydroxy17α-methylandrosta-1,4-dien-3-one, is an anabolic–androgenic steroid (AAS). It is the 4-chloro-substituted derivative of metandienone (dehydromethyltestosterone).
CDMT was the first original product of Jenapharm, an East German pharmaceutical company. The patent registration took place in 1961. The idea of combining the structures of 4-chlorotestosterone (clostebol) and metandienone originated from the chemist Albert Stachowiak. At the time this represented a unique dissociation of anabolic and androgenic effects after oral administration. The product had been introduced for clinical use from 1965 until 1994 when its production was discontinued.
CDMT was the key steroid administered to approximately 10,000 athletes from East Germany (GDR) as secret official policy, often without their knowing the nature of the "vitamins" they were forced to take. The doping program was run by the East German Government from about 1968 until 1989 when the GDR collapsed. The doping program was known as State Plan Topic 14.25. The doping was done in secret; it was only in the 1990s that Franke and Berendonk looked closely at the original archived information and discovered the true scope of just how well-planned and successful the doping regime had been (in terms of medal success and world record performances).
Following allegations by the German documentary of widespread doping the IOC kicked off a reanalysis of Beijing 2008 and London 2012 samples for all sports.
Weightlifters and sprinters in particular were found to have used CDMT. Most of the doped athletes coming from Russia, Ukraine, and Belarus.[unreliable source?] However,[clarification needed] the method developed by Grigory Rodchenkov in 2011 was used in 2016 to detect long-term metabolites of CDMT while retesting the athletes' Olympic samples.